Anavex Life Sciences Corp (AVXL)

[nidan7500]

Biogen adds $$1B in cap. based on this? kinda makes you wonder what a drug that really worked would be worth. I guess a LITTLE BRAIN BLEED is tolerable.

Tell me, if A2-73 performed like this would you be here? I would not.

“We continue to see optionality on lead pipeline Alzheimer’s drug, aducanumab, which, based on our expectation for (late-stage) data in (late 2019 or early 2020), could be one of the first disease-modifying drugs to reach the market,” the analysts wrote.

They predicted that, if the drug is approved, it could reach peak revenue of $12 billion, given the severity of the disease and that fact that the global costs of dementia grew 35 percent from 2010 to 2015, to $818 billion, and are projected to exceed $1 trillion sometime in 2018.

The analysts also gave a 50 percent chance that the drug will prove successful[/b]. Those odds struck many biotech investors and observers as overly optimistic for a disease in which no drugs for the past two decades have proven effective.